Skip to main content
HRMY
NASDAQ Life Sciences

Harmony Biosciences Q2 revenue jumps 30% to $261M, net income nearly doubles; pipeline advances with Pitolisant GR NDA accepted

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$36.75
Mkt Cap
$2.061B
52W Low
$25.52
52W High
$40.87
52W Position info
44% above low
Off High info
10% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

HRMY sits 44% above its 52-week low of $25.52.

Summary

Record Q2 2026 revenue of $261.3 million, a 30% increase, and net income of $75.4 million, nearly double the prior year, highlight the quarter. The Pitolisant GR NDA was accepted with an April 2027 PDUFA date, and the BP-205 IND is open, advancing the pipeline.


Key Events · Earnings and Guidance · HRMY

  • Record Q2 Revenue and Earnings

    Net product revenue reached $261.3 million in Q2 2026, up 30.3% year-over-year, driven by a 26.5% increase in units shipped and a 7% price increase. Net income nearly doubled to $75.4 million, or $1.28 per diluted share.

  • Pitolisant GR NDA Accepted

    The FDA accepted the NDA for Pitolisant GR with a target PDUFA date of April 1, 2027. This next-generation formulation could extend the pitolisant franchise into the 2040s.

  • BP-205 IND Open, Phase 1b Imminent

    The IND for BP-205, an orexin-2 receptor agonist, is now open. A Phase 1b study in sleep-deprived healthy volunteers will begin in Q3 2026, with topline data expected in early 2027.

  • Strong Balance Sheet

    Cash, cash equivalents, and investments totaled $962.5 million as of June 30, 2026, against $155 million in debt. The company has ample capital to fund operations and pipeline development.


Analysis · HRMY · Life Sciences

A standout quarter underscores the strength of the WAKIX franchise, with revenue climbing 30% year-over-year to $261.3 million and net income nearly doubling to $75.4 million. The balance sheet remains fortress-like at $962.5 million in cash and investments, providing ample runway for an expanding pipeline. Regulatory progress adds to the momentum: the FDA accepted the Pitolisant GR NDA with an April 2027 decision date, and the BP-205 IND is now open, with a Phase 1b study starting this quarter. These milestones, combined with strong commercial execution, reinforce the growth narrative. The only blemish is a new patent infringement lawsuit and antitrust counterclaims, but the core business momentum is undeniable.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HRMY was trading at $36.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HRMY - Latest Insights

HRMY
Nov 04, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.94
Real-time Price: $32.96 info
Change: -$2.98 (-8%) info
Market Cap: $1.936B info
HRMY
Nov 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.18
Real-time Price: $32.96 info
Change: -$3.22 (-9%) info
Market Cap: $1.936B info
HRMY
Nov 04, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.50
Real-time Price: $32.96 info
Change: -$3.54 (-10%) info
Market Cap: $1.936B info
HRMY
Oct 22, 2026, 3:57 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $36.03
Real-time Price: $32.96 info
Change: -$3.07 (-9%) info
Market Cap: $1.936B info
HRMY
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $32.96 info
Change: -$5.44 (-14%) info
Market Cap: $1.936B info